TABLE 1

Baseline characteristics, bronchiectasis severity indices and assessment of pulse-wave velocity and cardiac biomarkers in 101 patients with bronchiectasis

Subjects	101
Age years	61.0 (46.1–71.6)
Male	38 (38)
Current smoker	2 (2)
Ex-smoker	28 (28)
Pack-years (current/ex-smokers)	3.5 (1–15)
Body mass index kg·m⁻²	23.0 (20.9–25.7)
Systolic blood pressure mmHg	126 (115–139)
Diastolic blood pressure mmHg	80 (70–85)
Total cholesterol mmol·L⁻¹	4.8±0.4
Aetiology
Primary immunodeficiency^#	28 (28)
Idiopathic	21 (21)
Post-infective	19 (19)
Allergic bronchopulmonary aspergillosis	9 (9)
Other^¶	24 (24)
Long-term macrolide	19 (19)
Long-term nebulised antibiotic	3 (3)
Inhaled corticosteroid	42 (42)
FEV₁ % predicted	72.7±27.0
FEV₁ L	1.94±0.88
Exacerbation frequency events·year^-1	2 (1–3)
Time since last exacerbation days	171 (62–388)
Lobes involved on CT n	4 (3–6)
Pulmonary artery diameter mm	25.5±4.0
Pulmonary artery:aorta ratio	0.77 (0.70–0.84)
MRC dyspnoea score	2 (1–3)
Bronchiectasis severity index	5.5 (3–8)
Pulse-wave velocity m·s⁻¹	9.3 (8.1–10.9)
Troponin T μg·L⁻¹	0.006 (0.003–0.009)
NT-proBNP pmol·L⁻¹	10.0 (4.5–17.0)
Fibrinogen g·L⁻¹	3.31 (2.69–4.12)
C-reactive protein mg·L⁻¹	3.2 (1.0–7.7)

Data are presented as n, median (interquartile range), n (%) or mean±sd. FEV1: forced expiratory volume in 1 s; CT: computed tomography; MRC: Medical Research Council; NT-proBNP: N-terminal pro-brain natriuretic peptide. ^#: common variable immunodeficiency (n=23), IgG deficiency (n=4), X-linked agammaglobulinaemia (n=1); ^¶: rheumatoid arthritis (n=5), aspiration (n=3), Kartagener's syndrome (n=3), HIV (n=2), graft versus host disease (n=2), sarcoidosis (n=2), systemic lupus erythematosus (n=1), secondary immunodeficiency (n=1), surgery-related (n=1), post-radiotherapy (n=1), non-tuberculous mycobacteria (n=1), inflammatory bowel disease (n=1), Mounier-Kuhn syndrome (n=1).